Industry NewsRedHill Biopharma announces presentation of positive oral Opaganib Phase 2 data in COVID-19
Industry NewsRedHill Biopharma has received allowances for U.S. patent applications covering Opaganib and RHB-107 for COVID-19
Industry NewsRedHill Biopharma announces planned expansion of Opaganib global phase 2/3 COVID-19 study to the U.S
Industry NewsRedHill Biopharma announces first patient dosed in U.S. Phase 2/3 COVID-19 outpatient study with RHB-107
Industry NewsOpaganib by RedHill Biopharma submitted for approval of investigation for COVID-19 treatment
